Results 231 to 240 of about 304,614 (388)

The Selective Endothelin-A-Receptor Antagonist LU 135.252 Inhibits the Direct Arrhythmogenic Action of Endothelin-1

open access: bronze, 2000
Béla Merkely   +6 more
openalex   +1 more source

Endothelin‐A receptor antagonist inhibits angiotensin II and noradrenaline in man [PDF]

open access: green, 2001
René R. Wenzel   +5 more
openalex   +1 more source

Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re‐PHIRE

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1956-1964, June 2025.
Abstract Aims Despite receiving guideline‐directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH‐LHD) experience higher mortality and hospitalization rates than the general HF population.
Marcin Ufnal   +17 more
wiley   +1 more source

The effect and mechanism of endothelin-1-induced intracellular free calcium in human lung adenocarcinoma cells SPC-A1

open access: yesChinese Journal of Lung Cancer, 2008
Background and objective Endothelin-1 (ET-1) is a potent mitogen involved in cell growth in human lung adenocarcinoma cells SPC-A1. The increase in intracellular free calcium ([Ca2+]i) plays a great role in this process.
Juan ZHOU   +3 more
doaj  

Ferulic acid: extraction, estimation, bioactivity and applications for human health and food

open access: yesJournal of the Science of Food and Agriculture, Volume 105, Issue 8, Page 4168-4177, June 2025.
Abstract Ferulic acid ((E)‐3‐(4‐hydroxy‐3‐methoxy‐phenyl) prop‐2‐enoic acid) is a derivative of caffeic acid found in most plants. This abundant phenolic compound exhibits significant antioxidant capacity and a broad spectrum of therapeutic effects, including anti‐inflammatory, antimicrobial, anticancer, antidiabetic, cardiovascular and neuroprotective
Mukul Kumar   +13 more
wiley   +1 more source

Effects of an Endothelin Receptor Antagonist TAK-044 on Myocardial Energy Metabolism in Ischemia/Reperfused Rat Hearts

open access: bronze, 2000
Masaru Iimuro   +5 more
openalex   +1 more source

New Mechanisms and Therapeutic Targets in Systemic Lupus Erythematosus

open access: yesMedComm, Volume 6, Issue 6, June 2025.
Systemic lupus erythematosus (SLE) is a multiple organ involved autoimmune disorder with heterogeneous clinical manifestations. Despite hallmark features such as elevated type I interferon and the production of numerous autoantibodies, the underlying pathogenic mechanisms remain elusive.
Jingru Tian   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy